glp-1 regulatory news Recent updates on agonists: Current advancements & challenges Indications for GLP-1/GIP RA Summary

The recent position statement by the ADA advocating the use of both SGLT2i and GLP-1 RAs is encouraging, indicating that CKD in T2DM is under the spotlight

Human cell models based on microfluidics or organoids derived from human-derived induced pluripotent stem cells have become more realistic and perform better

Clinical research shows semaglutide produces average weight loss of approximately 15% at 12 months, while tirzepatide demonstrates even more dramatic results with up to 20% average weight loss in the same timeframe

This is a compounded injectable formulation dispensed by a licensed compounding pharmacy

Martin, you can explore whether this approach fits your health goals and lifestyle

For example, if youve had a shot in your shoulder, avoid using your bicep, shoulder, or upper pectoral muscles